Subscribe or Manage Preferences

“Arthritis is common among adults with heart disease, diabetes, or obesity, and the combination of arthritis and one of these chronic conditions has been associated with higher levels of physical inactivity, suggesting that arthritis-specific barriers to physical activity (concerns about worsening pain, damaging joints, and safely exercising) might be important concerns for adults with those conditions,” lead author Kamil E. Barbour, PhD, Arthritis Program, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA, and colleagues stated in the report.

There is limited information about the relative safety of selective cyclooxygenase-2 inhibitors. In particular, concerns exist regarding the adverse cardiovascular effects associated with celecoxib. In the aftermath of the withdrawal of rofecoxib from a placebo-controlled trial because of evidence of adverse cardiovascular outcomes associated with the cyclooxygenase-2 inhibitor, Steven E. Nissen, MD, Cardiologist, Cleveland Clinic, OH, and colleagues designed the 10-year PRECISION trial to compare the cardiovascular, gastrointestinal, and renal outcomes of celecoxib with those of naproxen or ibuprofen (Nissen SE, et al. N Engl J Med. 2016; 375:2519-2529).

A total of 1159 patient charts were abstracted; 230 patients had gout and OA, and 929 had gout without OA. Among patients with gout who were aged ≥61 years, 63.0% were identified as having comorbid OA. The majority of patients in the study were white (71.2%) and men (80.5%). Severity of gout was determined by physician global assessment, number of flares, physician-evaluated damage to organs and/or joints, and tophi.

Page 2 of 2
Results 11 - 13 of 13
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology